NCT02144051 - Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor

Interventions

DRUG

AZD5312

AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.

Trial Locations (4)

Unknown

Research Site, Sarasota

Research Site, Nashville

Research Site, Milwaukee

Research Site, London